Lisaftoclax: The development of lisaftoclax (APG2575) by Ascentage (www.ascentage.com) marked another selective BCL2 inhibitor that is orally active and potently inhibits BCL2.343 Its overall structure is based on venetoclax but displays key structural differences (Fig. 5e) leading to faster cellular uptake and slightly higher cell death induction in CLL cells. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.